Clearside Biomedical, Inc. financial data

Symbol
CLSD on Nasdaq
Industry
Pharmaceutical Preparations
Location
900 North Point Parkway, Suite 200, Alpharetta, GA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 518 % -39.8%
Debt-to-equity -281 % -146%
Return On Equity 170 %
Return On Assets -93.9 % -24.9%
Operating Margin -342 % +81.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 74.7M shares +20.5%
Common Stock, Shares, Outstanding 74.7M shares +21.1%
Entity Public Float 64M USD -20%
Common Stock, Value, Issued 74K USD +19.4%
Weighted Average Number of Shares Outstanding, Basic 74.7M shares +21.2%
Weighted Average Number of Shares Outstanding, Diluted 74.7M shares +21.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 7.52M USD +365%
Research and Development Expense 21.7M USD +13.6%
General and Administrative Expense 11.5M USD -2.73%
Operating Income (Loss) -25.8M USD +13.1%
Net Income (Loss) Attributable to Parent -33.5M USD +6.75%
Earnings Per Share, Basic -0.5 USD/shares +15.3%
Earnings Per Share, Diluted -0.5 USD/shares +15.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 18.2M USD -47.9%
Cash, Cash Equivalents, and Short-term Investments 29.4M USD
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 44K USD -85.6%
Assets, Current 29.8M USD -17.6%
Property, Plant and Equipment, Net 3.4M USD +65.7%
Operating Lease, Right-of-Use Asset 736K USD -26.1%
Other Assets, Noncurrent 30K USD 0%
Assets 33.9M USD -13.4%
Accounts Payable, Current 1.58M USD -16.4%
Employee-related Liabilities, Current 1.04M USD +6.8%
Accrued Liabilities, Current 3.7M USD +38.5%
Liabilities, Current 5.87M USD +11.4%
Operating Lease, Liability, Noncurrent 493K USD -38.1%
Other Liabilities, Noncurrent 480K USD
Liabilities 62.2M USD +40.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1K USD
Retained Earnings (Accumulated Deficit) -340M USD -10.9%
Stockholders' Equity Attributable to Parent -28.3M USD -469%
Liabilities and Equity 33.9M USD -13.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.85M USD -8.8%
Net Cash Provided by (Used in) Financing Activities 14.3M USD +4220%
Net Cash Provided by (Used in) Investing Activities -57K USD +50.4%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 74.7M shares +21.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.44M USD
Deferred Tax Assets, Valuation Allowance 84M USD +14%
Operating Lease, Liability 1.01M USD -21.2%
Depreciation 28K USD +86.7%
Payments to Acquire Property, Plant, and Equipment 57K USD -50.4%
Property, Plant and Equipment, Gross 4.39M USD +49.6%
Operating Lease, Liability, Current 370K USD +3.06%
Deferred Tax Assets, Operating Loss Carryforwards 52.7M USD +4.76%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 7.52M USD 0%
Operating Lease, Payments 99K USD +4.21%
Additional Paid in Capital 312M USD +3.36%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%